Janux Therapeutics Inc (JANX)
29.12 x 1 35.09 x 2
Post-market by (Cboe BZX)
31.74 +1.80 (+6.01%) 03/24/25 [NASDAQ]
29.12 x 1 35.09 x 2
Post-market 32.00 +0.26 (+0.82%) 16:16 ET
for Mon, Mar 24th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Sales | 10,588 | 8,083 | 8,612 | 3,637 | 0 |
Gross Profit | 10,588 | 8,083 | 8,612 | 3,637 | N/A |
Operating Expenses | 109,435 | 81,062 | 75,703 | 36,566 | 4,843 |
Operating Income | -98,847 | -72,979 | -67,091 | -32,929 | -4,843 |
Interest Expense | 0 | 0 | 0 | 0 | 206 |
Other Income | 29,853 | 14,686 | 4,032 | 257 | -1,735 |
Pre-tax Income | -68,994 | -58,293 | -63,059 | -32,672 | -6,784 |
Net Income Continuous | -68,994 | -58,293 | -63,059 | -32,672 | -6,784 |
Net Income | $-68,994 | $-58,293 | $-63,059 | $-32,672 | $-6,784 |
EPS Basic Total Ops | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 |
EPS Basic Continuous Ops | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 |
EPS Diluted Total Ops | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 |
EPS Diluted Continuous Ops | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 |
EPS Diluted Before Non-Recurring Items | -1.28 | -1.32 | -1.52 | -1.39 | N/A |
EBITDA(a) | $-107,372 | $-78,712 | $-68,433 | $-32,988 | $-4,830 |